Clarithromycin Susceptibility Testing of Mycobacterium avium Complex Using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium Chloride Microplate Assay with Middlebrook 7H9 Broth by Park, Young Kil et al.
Non-tuberculous mycobacteria (NTM) account for almost
a tenth of specimens smear positive for acid-fast bacilli in
Korea (1). Of these, half are Mycobacterium avium complex
(MAC) (2). Clarithromycin, a macrolide drug, forms the cor-
nerstone of MAC treatment (3) and is the only drug recom-
mended by the Clinical and Laboratory Standards Institute
(CLSI) for drug susceptibility testing (DST) of MAC (4). 
The oxidation-reduction dye, 2,3-diphenyl-5-thienyl-(2)-
tetrazolium chloride (STC) has advantages for rapid and con-
venient DST. The compound allows easy identification of po-
sitive cultures by producing dark precipitates that change the
solution from colorless to pink after solubilization; further,
even when added to media before inoculation, STC has no in-
hibitory effect on microorganisms (5). Some studies present
the advantages of STC-containing media to identify the grow-
th of microorganisms in 96-well microplates (5, 6). Therefore,
we applied a modification of standard methods to test the dr-
ug susceptibility of slowly growing mycobacteria (4) by ad-
ding STC. 
A total of 119 MAC strains (56 M. avium and 63 M. intra-
cellulare) isolated from clinical specimens, which had been
stored at -70℃at the Korean Institute of Tuberculosis (KIT),
were used. All isolates were subcultured initially on a slant
of Löwenstein-Jensen medium and thereafter in Middlebrook
7H9 broth (DIFCO Laboratory, Detroit, MI, U.S.A.) supple-
mented with 10% oleic acid-albumin-dextrose-catalase (O
ADC; BBL, Becton Dickinson, Sparks, MD, U.S.A.) at 37℃
for 5 days before DST. The bacterial suspension was adjust-
ed to McFarland No. 0.5 by adding sterile medium accord-
ing to CLSI guidelines (4). For susceptibility testing, STC-
containing and STC-free 7H9 broth was dispensed into mi-
croplate wells. The STC was purchased from Tokyo Kansei
Kogyo (Tokyo, Japan). Then, clarithromycin (Hanmi Pharm.
Co., Ltd, Seoul, Korea) stock solution was added to the wells
followed by serial dilutions to create the final concentrations
of 64 to 1 μ g/mL. The last three wells of each lane were filled
with 7H9 broth alone without clarithromycin for growth con-
trol. Later, 100 μ L of bacterial suspension was added to the
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Clarithromycin Susceptibility Testing of Mycobacterium avium
Complex Using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium Chloride Microplate
Assay with Middlebrook 7H9 Broth
A series of 119 Mycobacterium avium complex isolates were subjected to clar-
ithromycin susceptibility testing using microplates containing 2,3-diphenyl-5-thienyl-
(2)-tetrazolium chloride (STC). Among 119 isolates, 114 (95.8%) were susceptible
to clarithromycin and 5 were resistant according to the new and the standard method.
STC counts the low cost and reduces the number of procedures needed for sus-
ceptibility testing. 
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� BRIEF COMMUNICATION�wells. The final volume of each well was 200 μ L, and the final
concentration of bacterial inoculum was approximately 1.5
×105 CFU/mL. In STC-containing medium, the final STC
concentration was 50 μ g/mL. Before incubation, a suspension
of one antibiotic-free well was plated onto Middlebrook 7H10
agar (DIFCO) supplemented with 10% OADC (BBL) to de-
termine the inoculum size. Then, the microplates were incu-
bated at 37℃ until the control media wells (6-9 days) deve-
loped dark precipitates secondary to STC reduction. At that
point, the bacterial growth in the antibiotic-containing wells
was determined by adding 50 μ L of solubilizing agent. Sus-
ceptibility was defined by minimal inhibitory concentration
(MIC): susceptible at≤16 μ g/mL, intermediate at 32 μ g/mL,
and resistant at ≥64 μ g/mL at a broth pH of 6.8, as recom-
mended by CLSI (4). The MIC was defined as the lowest drug
concentration that prevented a change in the medium from
colorless to pink. 
The inoculation quantities of all 119 MAC isolates were
optimal according to confirmation on 7H10 agar media (data
not shown). The STC-containing and STC-free media resul-
ted in completely identical MICs in all tested strains. Among
the 119 MAC isolates, 114 (95.8%) were inhibited at con-
centrations ≤16 μ g/mL and therefore were classified as clar-
ithromycin-susceptible with no significant difference bet-
ween M. avium and M. intracellulare. Among these suscepti-
ble isolates, 109 were inhibited at 1 μ g/mL, 4 at 2 μ g/mL,
and only 1 at 16 μ g/mL. Only 5 MAC isolates were resistant
(Table 1). The decision for microbial growth in the micro-
plate wells was easier in STC-containing medium than in
STC-free medium because of the color indicator. 
Initial isolates from patients with previously untreated MAC
lung disease should be tested for clarithromycin susceptibil-
ity to establish baseline values, and many strains isolated from
different situations are reserved for DST (7, 8). Although the
MAC response to some antimicrobial agents may not be pre-
dicted reliably on the basis of current in vitro susceptibility
test methods, clinical response correlates with DST for the
macrolides (azithromycin and clarithromycin) (8). Therefore,
CLSI recommends that susceptibility of MAC isolates should
be evaluated for these drugs only (4). In the current study,
among 114 clarithromycin-susceptible isolates, all except
one were inhibited at ≤2 μ g/mL of clarithromycin. This is
consistent with the finding of Kawata et al. (9). STC, unlike
other tetrazolium compounds, can be added to the medium
before inoculation of bacteria (5) and avoids cumbersome pro-
cesses such as putting tetrazolium into the well to view cul-
tures after growth and adding extraction buffer to confirm
color change (10). 
In conclusion, we demonstrate that >95% of MAC isolates
from Korea are susceptible to clarithromycin, and that mod-
ification of the CLSI-recommended microplate DST method
using STC is useful.
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MIC (μ g/mL)
Species
No. of
isolates
≤1 248 ≥64 16 32
M. avium 56 49 4 3
M. intracellulare 63 60 1 2
Total 119 109 4 1 5
Table 1. MICs of clarithromycin for 119 M. avium complex iso-
lates determined by STC-containing and STC-free 7H9 micro-
plate methods
MIC, minimal inhibitory concentration.